Characterisation of transfusion-dependent prediabetes using continuous glucose monitoring: The Haemoglycare study
An erratum to this article was published (Diabetes Res Clin Pract, Jul 2025 ↗)
Authors' conclusion
CGM reliably detects prediabetes in 37 % of TDT patients. TAR140 > 6 % may serve as a diagnostic cutoff.
Study context
- Population
- Transfusion-dependent thalassemia patients with negative diabetes screening tests, and healthy controls
- Participants
- 39 patients
- Comparison
- Transfusion-Dependent Thalassemia (TDT) patients with negative diabetes screening vs healthy controls, using 7-day Continuous Glucose Monitoring (CGM)
- TDTn = 19
- Healthy controlsn = 20reference
- Outcome
- CGM glucose-related metrics
- Follow-up
- 7 days
Main finding
As reported in the abstract
TAR140 > 6 % · 7 days of CGM
TDT
37 %
7 of 19
Observational data: associations, not effects.
Secondary outcomes
Hyperglycemic (TAR140 > 6 %) vs euglycaemic (TAR140 ≤ 6 %) TDT patients
- Significant differences in GMI, mean glucose and TAR140%
- No differences in iron overload indexes
Original publication
Characterisation of transfusion-dependent prediabetes using continuous glucose monitoring: The Haemoglycare study. Diabetes Res Clin Pract. Published 1 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →